ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
49 announcements
Sat Kartar Life Limited submitted its Monitoring Agency Report for the half-year ended March 31, 2026. The report, issued by CARE Ratings, monitors the utilization of ₹33.80 Crore raised through its IPO. No deviations from the stated objects were reported during the period.
Sat Kartar Life Ltd reported revenue from operations of ₹110.6 Cr (+27.0% YoY) and net profit of ₹9.8 Cr (+63.3% YoY) for H2 FY26.
Sat Kartar Life Limited reported consolidated annual revenue of ₹203.12 Crore and net profit of ₹17.10 Crore for FY2026. Standalone revenue reached ₹193.84 Crore. The auditors issued an unmodified opinion, reflecting stable financial reporting and significant year-on-year growth in both top and bottom lines.
Sat Kartar Life Limited issued a corrigendum for a proposed preferential issue of 27,74,400 convertible warrants at ₹172 each, totaling ₹47.72 Crore. The funds will be utilized for healthcare expansion, strategic acquisitions, and technology branding. The warrants are convertible into equity shares within 18 months.
Sat Kartar Life Limited has scheduled a board meeting for May 5, 2026, to consider and approve audited standalone and consolidated financial results for the year ended March 31, 2026. The trading window remains closed until 48 hours after the results announcement.
Sat Kartar Life Limited (formerly Sat Kartar Shopping Limited) confirmed it does not qualify as a Large Corporate for FY 2025-26. The company reported outstanding borrowings of ₹2.39 Crore as of March 31, 2026. This mandatory SEBI disclosure clarifies the company's debt-raising compliance framework.
Sat Kartar Shopping Limited has convened an Extra-ordinary General Meeting (EGM) on May 13, 2026. Shareholders will vote on special resolutions regarding the preferential issuance of equity shares and warrants to non-promoter categories. The meeting will be conducted via video conferencing.
Sat Kartar Life Limited convened an EGM for May 13, 2026, to approve raising ₹48.59 Crore via preferential issuance of 50,400 equity shares and 27,74,400 warrants to non-promoter investors. Proceeds will fund healthcare expansion, strategic acquisitions, and technology branding over 24 months.
Sat Kartar Shopping Limited is acquiring the remaining stake in Plantomed Neutraceuticals Private Limited for ₹1.21 Crore to make it a wholly-owned subsidiary. The acquisition of the Ayurveda healthcare company aims to consolidate brands and expand the product portfolio. The transaction is expected to be completed by May 15, 2026.
Sat Kartar Shopping Limited approved the acquisition of a further 24% stake in Plantomed Neutraceuticals Private Limited for ₹1.21 Crore. This transaction will increase the company's control to 100%, making the target a wholly-owned subsidiary. The acquisition aims to consolidate branding and expand the company's Ayurveda and wellness product portfolio by May 2026.
Sat Kartar Life Limited approved the acquisition of an additional 24% stake in Plantomed Nutraceuticals Private Limited for ₹1.21 Crore. The transaction will make the target a wholly-owned subsidiary, aiding brand consolidation and aligning operations with the company's long-term vision. The deal is expected to close by May 15, 2026.
Sat Kartar Life Limited's board approved raising ₹49.79 Crore through the preferential issuance of equity shares and convertible warrants to non-promoter investors. Additionally, the company will acquire the remaining 24% stake in Plantomed Neutraceuticals for ₹1.21 Crore to make it a wholly-owned subsidiary. An EGM is scheduled for May 13, 2026, to seek shareholder approval.
Sat Kartar Shopping Limited has received formal approval from the National Stock Exchange of India to change its name to Sat Kartar Life Limited. The name change is effective in exchange records from April 23, 2026.
Sat Kartar Shopping Limited will change its name to Sat Kartar Life Limited, effective April 23, 2026. The company's trading symbol remains SATKARTAR on the NSE. This administrative update reflects a corporate rebranding.
Sat Kartar Shopping Limited has scheduled a board meeting for April 18, 2026, to consider a fund-raising proposal via a preferential issue. The company's trading window for designated persons is closed from April 15 to April 20, 2026, in compliance with insider trading regulations.
Sat Kartar Life Limited entered into a strategic collaboration with Jeena Sikho Lifecare Limited to build a technology-enabled Ayurveda healthcare ecosystem. The partnership integrates Sat Kartar's digital patient engagement and AI analytics with Jeena Sikho's clinical infrastructure. The collaboration aims to expand patient access to organized Ayurveda services through a revenue-sharing model linked to successful patient outcomes.
Sat Kartar Life Limited signed a strategic MOU with Jeena Sikho Lifecare Limited to integrate their Ayurveda healthcare ecosystems. The three-year partnership features a 15% revenue-sharing model on patient cases. This collaboration leverages Sat Kartar's digital infrastructure and Jeena Sikho's clinical facilities to expand integrated Ayurveda healthcare services.
Sat Kartar Life Limited submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations for the period ended March 31, 2026. The registrar, Skyline Financial Services, confirmed no physical share certificates were received for dematerialization during the quarter.
Sat Kartar Life Limited (formerly Sat Kartar Shopping Limited) clarified the non-applicability of Corporate Governance Report requirements for the quarter and year ended March 31, 2026. As an NSE SME listed entity, it claims exemption under SEBI LODR Regulation 15(2). The filing is supported by a certificate from a practicing company secretary.